10 employees
OrPro Therapeutics develops recombinant thioredoxin for the treatment of cystic fibrosis.
2006
$2.1M
from 1 investors over 1 rounds
Orpro Therapeutics raised $2.1M on July 19, 2022
Investors: united-states-department-of-defense